The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health ... alleging that they ...

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

which are negotiated with drug manufacturers and are tied to a drug’s list price. Insulin products with higher list prices result in higher rebates and fees for the PBMs, the complaint alleges.

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

The drug middlemen say they’re a necessary counterweight to the unchecked power of pharmaceutical companies to set prices. The insulin market is dominated by three manufacturers: Eli Lilly & Co ...

Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

In recent years, many patients like Mitchell have faced soaring insulin costs. These prices have been exacerbated by pharmacy benefit managers, or PBMs, middlemen between drug manufacturers and ...

Ben Hargreaves looks at why insulin ... drug pricing bill fails to take a holistic approach to addressing a system that drives affordability challenges for patients. By taking steps to hold ...

PBMs have long been seen as the “middlemen” getting in the ... 7 The FTC said that it is not targeting drug manufacturers for rising insulin prices, but it has not ruled out taking legal ...

Anyone who needs insulin to treat diabetes knows that the cost of the drug has skyrocketed in the last few years. The reason for the sharp ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

Hal Andrews, CEO at Trilliant Health, said as new drugs soared in popularity, drug companies have faced political pressure to ...